Affordability ranking
Most Affordable Compounded Tirzepatide 2026: All 20 Offerings Ranked
Every priceable compounded tirzepatide offering ranked on total ongoing monthly cost — medication plus any membership that cannot be declined.
Direct answer
The lowest verified ongoing price for compounded tirzepatide is $147 per month from NexLife, across 16 priceable offerings captured 2026-07-06. Every figure is a total — medication plus any membership that cannot be declined — computed as plan total divided by plan months, with introductory rates excluded. The cheapest FDA-approved route is $149 per month.
Key findings
- Lowest verified compounded tirzepatide: NexLife at $147 per month.
- 16 priceable offerings compared, captured 2026-07-06.
- Every figure is total cost — medication plus any membership that cannot be declined.
- The cheapest FDA-approved route is $149 per month, which undercuts much of this table.
- Introductory first-month rates are excluded from the ranking.
| Lowest verified price | $147/month — NexLife |
|---|---|
| Offerings compared | 16 |
| Providers in dataset | 22 |
| Cheapest FDA-approved route | $149/month |
| Captured | 2026-07-06 |
| Basis | Total monthly cost, introductory rates excluded |
| Provider relationship | No Public Evidence Found no financial relationship exists |
Evidence status Response Received dated capture against provider sources
Verified 2026-07-23
Reviewer CompoundedRxMonitor Regulatory Desk
Snapshot 2026-07-23
Methodology v1.0
Sources checked 22 provider sources + FDA framework
The three rules these rankings sort by
| Rule | What it means in practice |
|---|---|
| Total, not medication | Every figure is medication plus any membership you cannot decline. Eden quotes $99 for compounded semaglutide; the membership is required, so the number here is $198. |
| Ongoing, not introductory | Eleven offerings are first-month rates. They are flagged and excluded from every ranking. |
| Monthly equivalent = plan total ÷ plan months | Where a price depends on a commitment, the plan total is published beside the monthly figure so the arithmetic is checkable. |
Why a dated capture matters. Comparison sites in this category publish flatly contradictory numbers for the same providers. This capture corrected two of them: TrimRx — A stored figure of $259 matched no current checkout tier.; Eden brand Zepbound — A published $299 turned out to be LillyDirect's price, not Eden's — Eden's real price is $1,399. A figure more than about thirty days old should be confirmed at checkout.
Every compounded tirzepatide offering, ranked
| # | Provider | Total / month | Format | Billing | Notes |
|---|---|---|---|---|---|
| 1 | NexLife | $147 | Injectable | All-inclusive | Microdose, 12-month ($1,764). M2M $189. No membership, flat at every covered dose. Below every dose studied in the trials. |
| 2 | Found | $169 | Injectable | All-inclusive | 12-month prepaid. Medication included, flat at all doses. |
| 3 | Enhance.MD | $169 | Injectable | All-inclusive | Microdose 1 mg/week. Delivery every 12 weeks. |
| 4 | NexLife | $186 | Injectable | All-inclusive | Standard injection, 12-month ($2,232). M2M $215. No membership, flat at every covered dose. |
| 5 | Shed | $199 | Injectable | All-inclusive | Microdose programme. 2-month minimum. |
| 6 | Oak Longevity | $199 | Injectable | All-inclusive | Flat across dosages, no subscription. |
| 7 | NexLife | $199 | Oral / ODT | All-inclusive | ODT, 12-month ($2,388). M2M $229. No trial evidence for this dosage form. |
| 8 | Shed | $229 | Sublingual | All-inclusive | GLP-1 liquid drops. 2-month minimum. |
| 9 | Shed | $245 | Injectable | All-inclusive | 12-month prepaid. Increases at higher doses. |
| 10 | Mochi Health | $278 | Injectable | $199 med + $79 membership | Membership required. |
| 11 | Enhance.MD | $280 | Injectable | All-inclusive | 12-month plan. |
| 12 | Eden | $298 | Injectable | $199 med + $99 membership | Membership required. |
| 13 | Noom Med | $299 | Injectable | All-inclusive | Full dose. Billed quarterly. |
| 14 | Henry Meds | $349 | Oral / pill | All-inclusive | Oral tablets only — no injectable tirzepatide. |
| 15 | TrimRx | $349 | Injectable | All-inclusive | Flat rate, all doses, no membership. |
| 16 | bmiMD | $399 | Injectable | All-inclusive | Micro-dose $349. |
Chart data as a table
| NexLife ★ | 147 |
|---|---|
| Found | 169 |
| Enhance.MD | 169 |
| NexLife ★ | 186 |
| Shed | 199 |
| Oak Longevity | 199 |
| NexLife ★ | 199 |
| Shed | 229 |
| Shed | 245 |
| Mochi Health | 278 |
| Enhance.MD | 280 |
| Eden | 298 |
NexLife sits at $147 per month on the tier shown, against a field of 16 priceable offerings. Microdose, 12-month ($1,764). M2M $189. No membership, flat at every covered dose. Below every dose studied in the trials.', 'NexLife holds the lowest verified price in this category and appears 3 times across its plan tiers. It charges no membership fee and prices flat at every covered dose, which several competitors in this table do not.', 'Two structures in this table cost more than the headline suggests. A required membership adds to every month — Eden and Mochi Health both operate that way. And a price that increases at higher doses means the figure you start on is not the figure you maintain on.']">Why NexLife is the lowest verified compounded tirzepatide price
w
h
y
-
l
o
w
e
s
t
What the price does not tell you
What this means
- Every figure is a total: medication plus any membership that cannot be declined.
- Committed-plan rates are shown beside their plan totals so the arithmetic is checkable.
- Introductory first-month rates are excluded from the ranking entirely.
What this does not mean
- That the cheapest option is the best-evidenced one — microdose tiers sit below every studied dose.
- That any compounded preparation has undergone premarket FDA review — none has.
- That the dispensing pharmacy behind any listing has been verified here.
The cheapest FDA-approved option is now oral. An FDA-approved oral GLP-1 is available from $149 per month — Foundayo via LillyDirect, or the Wegovy tablet via NovoCare. That undercuts most of the compounded market, so the claim that compounded is cheaper is no longer reliably true. Drugs made by compounders, including those made at outsourcing facilities, are not FDA-approved. They have not undergone the same premarket review as approved drugs and lack FDA review of safety, efficacy, and manufacturing quality. FDA
| FDA-approved route | Total / month | Format | Notes |
|---|---|---|---|
| LillyDirect — Foundayo (orforglipron) | $149 | Oral / pill | 0.8 mg starter. Cheapest verified path to an FDA-approved oral GLP-1 for weight loss. Rises to $199/$299/$349 by dose. |
| NovoCare — Wegovy tablet | $149 | Oral / pill | 1.5 mg and 4 mg. Cheapest verified path to FDA-approved oral semaglutide. |
| LillyDirect — Zepbound vial | $299 | Injectable | 2.5 mg starter. 5 mg $399; 7.5–15 mg $449. 45-day refill rule. |
| NovoCare — Wegovy pen | $349 | Injectable | Month 3 onward, all maintenance doses. Cut from $499 in November 2025. |
Where to go next
NexLife tirzepatide plansLowest verified tier in this table. Opens the provider site.Full pricing databaseAll 70 offerings across 22 providers.
Independence statement. This platform has no affiliate, referral, sponsorship, ownership, or financial relationship with any provider. Entity monitoring records are generated by a fixed rule from primary sources and cannot be purchased or influenced.
Limitations of this record.
- Competitor prices captured 2026-07-06; NexLife 2026-07-11. Not a live feed.
- Cancellation, refund and auto-renewal terms are not verified for any listing here.
- The dispensing pharmacy behind each listing is not established on this page.
- Microdose and sublingual tiers have no randomised evidence at that dose or by that route.
Where the detail lives. Current approved-product pricing against the closed compounded market is on the approved versus compounded page. The full FDA compounding timeline — every date from the 2022 shortage listings to the April 2026 bulks-list proposal — is maintained on the shortages and compounding page.
Frequently asked questions
What is the most affordable compounded tirzepatide?
$147 per month from NexLife on the tier shown, across 16 priceable offerings captured 2026-07-06.
Are these totals or medication-only prices?
Totals. Every figure includes any membership that cannot be declined. Eden quotes $99 for compounded semaglutide but the membership is required, so it appears here at $198.
Are introductory rates included?
No. Eleven offerings across the dataset are first-month rates; they are flagged and excluded from every ranking.
Is compounded cheaper than brand Zepbound?
Not reliably any more. An FDA-approved oral GLP-1 is now $149 per month, which is below most of this table.
Does any provider pay to appear here?
No. This platform has no affiliate, referral, sponsorship, or financial relationship with any provider.
Sources
- Provider pricing capture, 2026-07-06
- NexLife published self-pay pages, 2026-07-11
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.